Furanitini sales revenue for 2019 was $17.6 million.

In September 2018, the furanquine was approved by the State Drug Administration of China for use in the past for chemotherapy based on fluorourery, o's saliplatin and Ilitikang, as well as for metastatic colorectal cancer patients who have received or are not suitable for anti-VEGF therapy, anti-EGFR treatment (RAS wild type) and are the first VEGF inhibitors developed from scratch by a local Chinese enterprise.
furanquine in 2019 sales of $17.6 million, but Q4 revenue of only $500,000.
about 3,000 patients were treated with chloroquine in 2019.
November 2019, the price of the enoquinetinib was successfully selected into the 2019 national health insurance catalogue, and after January 1, 2020, the price of the epinemine capsulewas was reduced to RMB1984.5/box (1mg x21 specification) and RMB 2646/box (5mg x7 specification), a decrease of more than 60%.
this provides the foundation for its expanded patient accessibility in China.
in the first two months of 2020 alone, the company generated sales of $6.6 million.
Sofantini is a new type of oral VEGFR/FGFR/CSF-1R multi-target inhibitor.
November 2019, China's State Drug Administration accepted the application for a new drug for the treatment of advanced non-pancreatic neuroendocrine tumors by surufatinib and included it in the priority review.
March 2019, Sofantini also launched a phase IIb/III clinical trial of biliary cancer in China to improve the efficacy and safety of advanced biliary cancer (BTC) developed after first-line chemotherapy treatment sedatives with Bisofaninib (HMPL-012 or sulfatinib) and Caperitabin.
also conducted a clinical trial of Trepri's monoantine-combined sofantinib for a variety of advanced solid tumors.
2020, Hutchison Pharma will launch a Phase II study of Cindy Singli singifada/Trepri monoantino/sofentinib in China;
.